Table of Contents

1 Study Coverage

• 1.1 Cancer Diagnostics Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Cancer Diagnostics Market Size Growth Rate by Product
  • 1.4.2 Platform-based
  • 1.4.3 Instrument-based
• 1.5 Market by End User
  • 1.5.1 Global Cancer Diagnostics Market Size Growth Rate by End User
  • 1.5.2 Breast Cancer
  • 1.5.3 Lung Cancer
  • 1.5.4 Colorectal Cancer
  • 1.5.5 Melanoma
  • 1.5.6 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Cancer Diagnostics Market Size
  • 2.1.1 Global Cancer Diagnostics Revenue 2014-2025
  • 2.1.2 Global Cancer Diagnostics Sales 2014-2025
• 2.2 Cancer Diagnostics Growth Rate by Regions
  • 2.2.1 Global Cancer Diagnostics Sales by Regions
  • 2.2.2 Global Cancer Diagnostics Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Cancer Diagnostics Sales by Manufacturers
  • 3.1.1 Cancer Diagnostics Sales by Manufacturers
  • 3.1.2 Cancer Diagnostics Sales Market Share by Manufacturers
  • 3.1.3 Global Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
• 3.2 Cancer Diagnostics Revenue by Manufacturers
  • 3.2.1 Cancer Diagnostics Revenue by Manufacturers (2014-2019)
  • 3.2.2 Cancer Diagnostics Revenue Share by Manufacturers (2014-2019)
• 3.3 Cancer Diagnostics Price by Manufacturers
• 3.4 Cancer Diagnostics Manufacturing Base Distribution, Product Types
  • 3.4.1 Cancer Diagnostics Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Cancer Diagnostics Product Type
  • 3.4.3 Date of International Manufacturers Enter into Cancer Diagnostics Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Cancer Diagnostics Sales by Product
• 4.2 Global Cancer Diagnostics Revenue by Product
• 4.3 Cancer Diagnostics Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Cancer Diagnostics Breakdown Data by End User

6 North America

• 6.1 North America Cancer Diagnostics by Countries
  • 6.1.1 North America Cancer Diagnostics Sales by Countries
  • 6.1.2 North America Cancer Diagnostics Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Cancer Diagnostics by Product
• 6.3 North America Cancer Diagnostics by End User

7 Europe

• 7.1 Europe Cancer Diagnostics by Countries
  • 7.1.1 Europe Cancer Diagnostics Sales by Countries
  • 7.1.2 Europe Cancer Diagnostics Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Cancer Diagnostics by Product
• 7.3 Europe Cancer Diagnostics by End User

8 Asia Pacific

• 8.1 Asia Pacific Cancer Diagnostics by Countries
  • 8.1.1 Asia Pacific Cancer Diagnostics Sales by Countries
  • 8.1.2 Asia Pacific Cancer Diagnostics Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Cancer Diagnostics by Product
• 8.3 Asia Pacific Cancer Diagnostics by End User

9 Central & South America

• 9.1 Central & South America Cancer Diagnostics by Countries
  • 9.1.1 Central & South America Cancer Diagnostics Sales by Countries
  • 9.1.2 Central & South America Cancer Diagnostics Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Cancer Diagnostics by Product
• 9.3 Central & South America Cancer Diagnostics by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Cancer Diagnostics by Countries
  • 10.1.1 Middle East and Africa Cancer Diagnostics Sales by Countries
  • 10.1.2 Middle East and Africa Cancer Diagnostics Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Cancer Diagnostics by Product
• 10.3 Middle East and Africa Cancer Diagnostics by End User

11 Company Profiles

• 11.1 Becton, Dickinson and Company
  • 11.1.1 Becton, Dickinson and Company Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Becton, Dickinson and Company Cancer Diagnostics Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Becton, Dickinson and Company Cancer Diagnostics Products Offered
  • 11.1.5 Becton, Dickinson and Company Recent Development
• 11.2 GE Healthcare
  • 11.2.1 GE Healthcare Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 GE Healthcare Cancer Diagnostics Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 GE Healthcare Cancer Diagnostics Products Offered
  • 11.2.5 GE Healthcare Recent Development
• 11.3 Abbott
  • 11.3.1 Abbott Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Abbott Cancer Diagnostics Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Abbott Cancer Diagnostics Products Offered
  • 11.3.5 Abbott Recent Development
• 11.4 Roche
  • 11.4.1 Roche Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Roche Cancer Diagnostics Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Roche Cancer Diagnostics Products Offered
  • 11.4.5 Roche Recent Development
• 11.5 Thermo Fisher Scientific
  • 11.5.1 Thermo Fisher Scientific Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Thermo Fisher Scientific Cancer Diagnostics Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Thermo Fisher Scientific Cancer Diagnostics Products Offered
  • 11.5.5 Thermo Fisher Scientific Recent Development
• 11.6 Agilent Technologies
  • 11.6.1 Agilent Technologies Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Agilent Technologies Cancer Diagnostics Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Agilent Technologies Cancer Diagnostics Products Offered
  • 11.6.5 Agilent Technologies Recent Development
• 11.7 Illumina
  • 11.7.1 Illumina Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Illumina Cancer Diagnostics Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Illumina Cancer Diagnostics Products Offered
  • 11.7.5 Illumina Recent Development
• 11.8 Siemens Healthcare
  • 11.8.1 Siemens Healthcare Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Siemens Healthcare Cancer Diagnostics Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Siemens Healthcare Cancer Diagnostics Products Offered
  • 11.8.5 Siemens Healthcare Recent Development
• 11.9 C.R. Bard
  • 11.9.1 C.R. Bard Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 C.R. Bard Cancer Diagnostics Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 C.R. Bard Cancer Diagnostics Products Offered
  • 11.9.5 C.R. Bard Recent Development

12 Future Forecast

• 12.1 Cancer Diagnostics Market Forecast by Regions
  • 12.1.1 Global Cancer Diagnostics Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Cancer Diagnostics Revenue Forecast by Regions 2019-2025
• 12.2 Cancer Diagnostics Market Forecast by Product
  • 12.2.1 Global Cancer Diagnostics Sales Forecast by Product 2019-2025
  • 12.2.2 Global Cancer Diagnostics Revenue Forecast by Product 2019-2025
• 12.3 Cancer Diagnostics Market Forecast by End User
• 12.4 North America Cancer Diagnostics Forecast
• 12.5 Europe Cancer Diagnostics Forecast
• 12.6 Asia Pacific Cancer Diagnostics Forecast
• 12.7 Central & South America Cancer Diagnostics Forecast
• 12.8 Middle East and Africa Cancer Diagnostics Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Cancer Diagnostics Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

This report manily covers cancer diagnostics market.Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
North America is expected to account for the largest share in the cancer diagnostics market, followed by Europe and Asia. 
The Asian market is slated to grow at the highest CAGR in the coming five years and serves as a revenue pocket for the companies operating in the cancer diagnostics market.
The global Cancer Diagnostics market is valued at 8990 million US$ in 2018 and will reach 23200 million US$ by the end of 2025, growing at a CAGR of 12.6% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Cancer Diagnostics market based on company, product type, end user and key regions.

This report studies the global market size of Cancer Diagnostics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Cancer Diagnostics in these regions.
This research report categorizes the global Cancer Diagnostics market by top players/brands, region, type and end user. This report also studies the global Cancer Diagnostics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Becton, Dickinson and Company
GE Healthcare
Abbott
Roche
Thermo Fisher Scientific
Agilent Technologies
Illumina
Siemens Healthcare
C.R. Bard

Market size by Product
Platform-based
Instrument-based
Market size by End User
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Cancer Diagnostics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Cancer Diagnostics market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Cancer Diagnostics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Cancer Diagnostics submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Cancer Diagnostics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Cancer Diagnostics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.